U.S., April 15 -- ClinicalTrials.gov registry received information related to the study (NCT07529535) titled 'A Phase I/II Study of ALK-N001 for Injection in Patients With Advanced Solid Tumors.' on April 08.
Brief Summary: This study is a multicenter, open-label, dose-escalation plus rollover and cohort expansion Phase I/II clinical trial conducted in patients with advanced solid tumors, including esophageal squamous cell carcinoma, small cell lung cancer, and gastric/gastroesophageal junction adenocarcinoma. It aims to evaluate the tolerability, safety, pharmacokinetics, and efficacy of ALK-N001 for injection as monotherapy in the treatment of advanced solid tumors such as esophageal squamous cell carcinoma, small cell lung cancer, and g...